An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2017-09-25
• Target enrollment: 0
• Participant gender: All

Summary

A study comparing the usability of the Autoinjector and Pre-filled Syringe of SB4 in Subjects with Rheumatoid Arthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Bioepis Co., Ltd.
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Subjects are male or female aged 18-55 years at the time of signing the informed consent form.

Exclusion Criteria:

• Have been treated previously with monoclonal antibody agent including any tumour necrosis factor inhibitor except SB4.